Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
22.16
-0.28 (-1.25%)
At close: Feb 13, 2026, 4:00 PM EST
22.54
+0.38 (1.71%)
After-hours: Feb 13, 2026, 7:38 PM EST
Immunome Stock Forecast
Stock Price Forecast
The 10 analysts that cover Immunome stock have a consensus rating of "Strong Buy" and an average price target of $32.1, which forecasts a 44.86% increase in the stock price over the next year. The lowest target is $22 and the highest is $40.
Price Target: $32.1 (+44.86%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Immunome stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 6 |
| Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 9 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +80.51% | Feb 12, 2026 |
| Wedbush | Wedbush | Buy Reiterates $31 | Buy | Reiterates | $31 | +39.89% | Jan 15, 2026 |
| Lake Street | Lake Street | Strong Buy Maintains $22 → $32 | Strong Buy | Maintains | $22 → $32 | +44.40% | Dec 16, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $18 → $40 | Buy | Maintains | $18 → $40 | +80.51% | Dec 16, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $25 → $35 | Strong Buy | Maintains | $25 → $35 | +57.94% | Dec 16, 2025 |
Financial Forecast
Revenue This Year
7.38M
from 9.04M
Decreased by -18.43%
Revenue Next Year
8.23M
from 7.38M
Increased by 11.53%
EPS This Year
-2.32
from -5.00
EPS Next Year
-2.67
from -2.32
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 10.4M | 27.9M | ||||
| Avg | 7.4M | 8.2M | ||||
| Low | 6.8M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 15.5% | 278.7% | ||||
| Avg | -18.4% | 11.5% | ||||
| Low | -25.2% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.96 | -2.02 | ||||
| Avg | -2.32 | -2.67 | ||||
| Low | -2.36 | -3.45 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.